Clinical Trial Update: 5G-PEARL: Paxalisib in Malignant Brain Tumours [Phase 1, Phase 2]

View source ↗

Summary

This update describes a Phase 1/2 clinical trial (5G-PEARL) evaluating paxalisib in malignant brain tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Paxalisib (GDC-0084)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Malignant Primary Gliomas, Glioblastoma Multiforme (GBM) | Phase 1, Phase 2 | Status: RECRUITING